Ligand Pharmaceuticals Management
Management criteria checks 3/4
Ligand Pharmaceuticals' CEO is Todd Davis, appointed in Dec 2022, has a tenure of 1.25 years. total yearly compensation is $5.82M, comprised of 0.8% salary and 99.2% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $4.30M. The average tenure of the management team and the board of directors is 1.3 years and 14.3 years respectively.
Key information
Todd Davis
Chief executive officer
US$5.8m
Total compensation
CEO salary percentage | 0.8% |
CEO tenure | 1.3yrs |
CEO ownership | 0.3% |
Management average tenure | 1.3yrs |
Board average tenure | 14.3yrs |
Recent management updates
Recent updates
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
Dec 31Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Dec 03Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?
Oct 11Ligand's Ailing Remdesivir Cash Cow
Oct 11Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Aug 19Ligand: 2021 Is Pivotal
Jul 16CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | US$54m |
Sep 30 2023 | n/a | n/a | US$21m |
Jun 30 2023 | n/a | n/a | US$41m |
Mar 31 2023 | n/a | n/a | US$51m |
Dec 31 2022 | US$6m | US$49k | -US$5m |
Sep 30 2022 | n/a | n/a | US$23m |
Jun 30 2022 | n/a | n/a | US$27m |
Mar 31 2022 | n/a | n/a | US$45m |
Dec 31 2021 | US$328k | n/a | US$76m |
Sep 30 2021 | n/a | n/a | US$68m |
Jun 30 2021 | n/a | n/a | US$48m |
Mar 31 2021 | n/a | n/a | US$39m |
Dec 31 2020 | US$329k | n/a | US$7m |
Sep 30 2020 | n/a | n/a | -US$16m |
Jun 30 2020 | n/a | n/a | -US$25m |
Mar 31 2020 | n/a | n/a | -US$61m |
Dec 31 2019 | US$350k | n/a | US$629m |
Sep 30 2019 | n/a | n/a | US$594m |
Jun 30 2019 | n/a | n/a | US$677m |
Mar 31 2019 | n/a | n/a | US$764m |
Dec 31 2018 | US$343k | n/a | US$143m |
Sep 30 2018 | n/a | n/a | US$179m |
Jun 30 2018 | n/a | n/a | US$120m |
Mar 31 2018 | n/a | n/a | US$53m |
Dec 31 2017 | US$283k | n/a | US$13m |
Compensation vs Market: Todd's total compensation ($USD5.82M) is about average for companies of similar size in the US market ($USD5.10M).
Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.
CEO
Todd Davis (62 yo)
1.3yrs
Tenure
US$5,824,396
Compensation
Mr. Todd C. Davis, Ph D., serves as an Independent Director of Chromocell Therapeutics Corporation since January 2023 and its Chairman of the Board. He is Chief Executive Officer at Ligand Pharmaceuticals...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 1.3yrs | US$5.82m | 0.34% $ 4.3m | |
President & COO | 1.3yrs | US$6.54m | 0.59% $ 7.4m | |
Chief Financial Officer | 1.3yrs | US$3.27m | 0.17% $ 2.1m | |
Chief Legal Officer & Secretary | 1.3yrs | US$3.25m | 0.13% $ 1.6m | |
Senior Vice President of Investments & Business Development | no data | no data | no data | |
Head of Investor Relations | no data | no data | no data | |
Director of Corporate Development | no data | no data | no data | |
Chief People Officer | 17.2yrs | no data | no data | |
Senior Vice President of Biology & Scientific Affairs | 6.2yrs | no data | no data | |
Senior Vice President of Technical Operations & QA - Capitsol | 6.2yrs | no data | no data | |
Senior VP & CBO Protein Expression Business | no data | no data | no data | |
Senior VP of Clinical Strategy & Investments | less than a year | no data | no data |
1.3yrs
Average Tenure
53yo
Average Age
Experienced Management: LGND's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 17yrs | US$5.82m | 0.34% $ 4.3m | |
Independent Chairman | 21yrs | US$586.60k | 0.22% $ 2.7m | |
Independent Director | 13.1yrs | US$481.16k | 0.15% $ 1.9m | |
Independent Director | 15.6yrs | US$571.60k | 0.16% $ 2.0m | |
Independent Director | 17.5yrs | US$483.66k | 0.44% $ 5.6m | |
Scientific Advisor | no data | no data | no data | |
Independent Director | 1.8yrs | US$490.57k | 0.017% $ 214.0k | |
Independent Director | 6.6yrs | US$436.41k | 0.031% $ 386.6k | |
Director | less than a year | no data | no data |
14.3yrs
Average Tenure
63yo
Average Age
Experienced Board: LGND's board of directors are seasoned and experienced ( 14.3 years average tenure).